The in vitro activity of a new investigational cephalosponn, Ro 13-9904, was compared with those of four cephalosporins (cephalothin, cefamandole, cefoxitin, and moxalactam), five semisynthetic penicillins (mezlocillin, piperacillin, carbenicillin, ticarcillin, and azlocillin), and the aminoglycoside tobramycin. Ro Gram-positive cocci and a few indole-positive Proteus isolates were cultured from various sites of hospitalized patients, some of whom did not have cancer. All isolates were maintained in stock by lyophilization or ultrafreezing methods. Penicillin G-resistant S. aureus isolates were defmed arbitrarily as those isolates resistant to 25.0 jg or more of penicillin G per ml as determined by a broth dilution method. Penicillin Gsusceptible strains were inhibited by 0.10 ,ug/ml. 
Within the last decade, there has been a proliferation of new beta-lactam antibiotics resulting from the modification of the side chains of the penicillin, cephalosporin, and cephamycin nuclei. These new analogs have increased substantially the spectrum of activity of penicillins and cephalosporins. Semisynthetic penicillins such as piperacillin and azlocillin are active against Pseudomonas aeruginosa, Serratia marcescens, and Enterobacter spp. (1, 7) . Cephalosporin analogs such as moxalactam and cefoperazone are active not only against the above organisms but also against anaerobic organisms such as Bacteroides fragilis (3) .
Ro 13-9904 is a new, semisynthetic cephalosporin which has demonstrated broad-spectrum activity in vitro (Fig. 1 ). Ro 13-9904 was tested to determine its in vitro efficacy against clinical isolates obtained from patients located in a hospital where antibiotics are used extensively and, as a consequence, many isolates are resistant to multiple antibiotics. The activity of Ro 13-9904 was compared with those of 10 other commercial and investigational antibiotics. This new antibiotic was found to be more active in vitro than any commercially available cephalosporin and more active than most of the investigational cephalosporins studied.
MATERIALS AND METHODS
Susceptibility tests were performed on 497 clinical isolates of gram-negative bacilli and 172 clinical isolates of gram-positive cocci by using the Dynatech broth microtiter system. Organisms were tested in duplicate simultaneously and included 105 isolates of P. aeruginosa, 100 inoculated using a calibrated micro-pipette dropper delivering 0.05 ml of the test organism. Microtiter plates used for comparative antibiotic studies were dispensed at a volume of 0.10 ml of the appropriate antibiotic and concentration per well. These plates were inoculated automatically using a Dynatech MIC-2000 inoculator. All plates were frozen at -70°C for no longer than 4 weeks and were thawed just before use.
The susceptibility of some isolates of Enterobacter spp. and P. aeruginosa to Ro 13-9904 was determined using the Abbott MS-2 system as well as by microtiter. In the MS-2 system, the antibiotic was diluted serially in a multichambered cuvette. Each isolate was grown overnight in Mueller-Hinton broth and diluted to a concentration of 106 organisms per ml. The last chamber contained no antibiotic and was used as a control. To each chamber of the cuvette, 0.05 ml of inoculum was added. The cuvette was incubated in the machine, which maintained the temperature at 37°C and provided for the continuous agitation of the cuvette. At 5-min intervals, growth was detected turbidimetrically in each chamber and recorded. A growth curve was generated from these data. Susceptibility or resistance was determined by comparing the slopes of these growth curves with the slope of the growth curve produced by the control chamber.
The minimum inhibitory concentrations (MICs) of Ro 13-9904 against 10 isolates of Pseudomonas in Mueller-Hinton broth were determined and compared using three different methods, the microtiter and the MS-2 systems, as indicated above, and the standard tube dilution method described by Washington and Barry (8) .
The effect of pH on drug activity was determined by adjusting the pH of Mueller-Hinton broth to 6.4, 7.2, and 8.0, using 1 N NaOH and 1 N HCl. The effect of media on the activity of Ro 13-9904 was studied with Mueller-Hinton broth, Trypticase soy broth, brain heart infusion broth, and nutrient broth. The effect of inoculum size was determined using concentrations of 105 and 10' cells per ml. The same 10 strains each of E. coli, Klebsiella spp., Enterobacter spp., and P. aeruginosa were used for all of these studies.
The MIC was defined as the lowest concentration of drug which suppressed the growth of gram-negative bacilli, enterococci, and S. aureus after 18 (4) , certain strains of Enterobacter displayed a "skipping"
effect. These isolates were tested on the Abbott MS-2 system, and this effect was confirmed.
Moxalactam was the most active drug against indole-positive Proteus spp., inhibiting 90% of isolates at a concentration of 0.39,tg/ml. A concentration of 3.12 ,ug of Ro 13-9904 per ml was required to inhibit the same proportion of isolates. Mezlocillin and piperacillin were only moderately active against K. pneumoniae, inhibiting 50% of the strains at a concentration of 25.0 Ag/ml. The remaining antibiotics showed excellent activity against the Klebsiella isolates. Both Ro 13-9904 and moxalactam inhibited 90% of the isolates at a concentration of 0.10 ,ug/ml. E. coli was susceptible to all antibiotics tested at low concentrations.
The results in Table 2 summarize the activity of Ro 13-9904, moxalactam, carbenicillin, piperacllin, mezlocillin, ticarcillin, azlocillin, and tobramycin against isolates of P. aeruginosa. Tobramycin was the most active drug, inhibiting 90% of the strains at a concentration of 0.39 ,g! ml. Piperacillin and azlocillin showed comparable activity, inhibiting 75% of the isolates of Pseudomonas at a concentration of 12.5 ,g/ml. Ro 13-9904 showed only limited activity.
Varying the pH from 6.4 to 8.0 had no significant effect on the potency of Ro 13-9904. Media variation studies performed with Mueller-Hinton medium, Trypticase soy broth, brain heart infusion broth, and nutrient broth showed that Ro 13-9904 is slightly less active in nutrient ' Ten isolates of each were tested. this institution have characteristically been more resistant to antibiotics than expected, probably due to the necessity for extensive antibiotic usage.
Ro 13-9904 was only minimally active against isolates of P; aeruginosa. The most active drug against P. aeruginosa was tobramycin, inhibiting 90% of all isolates at a concentration of 0.39 pug/ml. Piperacillin and azlocillin were the most active beta-lactam antibiotics, inhibiting 50% of the isolates of P. aeruginosa at a concentration of 12.5 pug/ml. Piperacillin, azlocillin, and mezlocillin were less active against P. aeruginosa in this study than in previous studies (1, 2, 7) . This difference may be explained in part by the fact that the present studies were performed using a different technique. Also, more recent clinical isolates of P. aeruginosa were tested. This suggests that organisms may be becoming increasingly resistant to these antibiotics at this institution.
Ro 13-9904 inhibited 90% of the streptococcal isolates (except enterococci) at a concentration of 0.10 pg/ml. All staphylococcal isolates were inhibited at a concentration of 6.25 pAg/ml. This activity is good, but it is not superior to the activity demonstrated by conventional cephalosporins such as cephalothin (6) .
The potency of Ro 13-9904 was not affected by varying the pH of the media, and it was only slightly less active in nutrient broth than in other media tested. However, an increase in organism concentration from 105 to i07 resulted in a fourfold or greater decrease in activity.
